 |
 |

In This Issue of Archives of Internal Medicine
Arch Intern Med. 2001;161:1951.
Timing of Initial Administration of Low-Molecular-Weight Heparin Against
Deep Vein Thrombosis Following Elective Hip Arthroplasty
Perioperative and postoperative venous thrombosis are common in patients
undergoing elective hip surgery. Current prophylactic regimens include oral
anticoagulants and subcutaneous low-molecular-weight heparin initiated 12
hours or more before or after surgery. Recent clinical trials suggest low-molecular-weight
heparin initiated closer to surgery is more effective than current clinical
practice. Hull et al performed a systematic review of the literature to assess
the efficacy and safety of low-molecular-weight heparin administered at different
times in relation to surgery vs oral anticoagulant prophylaxis. The results
indicated that low-molecular-weight heparin initiated in close to surgery
resulted in absolute risk reduction of 11% to 13% for deep vein thrombosis,
corresponding to relative risk reduction of 43% to 55% compared with oral
anticoagulants. Low-molecular-weight heparin initiated remote from surgery
(12 to 24 hours postoperatively or 12 hours preoperatively) was not more effective
than oral anticoagulants. Low-molecular-weight heparin initiated soon after
surgery at half the usual dose was not associated with a significant increase
in major bleeding rates.
(SEE ARTICLE)
A First-Tier Rapid Assay for the Serodiagnosis of Borrelia burgdorferi Infection
The rapid assay developed in this study is equally sensitive and more
specific than a commercial whole cell enzyme-linked immunosorbent assay, which
is frequently used as a first-tier assay for the serodiagnosis of Lyme disease.
It is suited for the physician's office, which streamlines the 2-tier system
recommended by the Centers for Disease Control and Prevention by allowing
the physician to determine if a Western blot is indicated at the time of the
initial office visit.
(SEE ARTICLE)
Prevalence of Gastrointestinal Symptoms Associated With Diabetes Mellitus:
A Population-Based Survey of 15 000 Adults
Gastrointestinal symptoms are reportedly common in diabetes mellitus,
but the available epidemiological data are conflicting and can be challenged
on methodological grounds. In this cross-sectional study of 15 000 adults
in Sydney, Australia, the authors examined the relationship between diabetes
mellitus and troublesome gastrointestinal symptoms. Unlike most previous studies,
the survey was done in a community setting and incorporated both an adequate
control group and a representative diabetic population of all ages and grades
of severity. The diabetic population comprised 4.9% of the total population.
The authors found that for all gastrointestinal symptoms, occurrence was significantly
more frequent in individuals with diabetes compared with controls, even when
they adjusted for potential confounding factors. Gastrointestinal symptoms
were strongly associated with poor glycemic control but not with the duration
of diabetes or the type of diabetic treatment. The study suggests that irreversible
autonomic nerve dysfunction is unlikely to be the only factor that explains
the observed higher prevalence of gastrointestinal symptoms in diabetes mellitus.
(SEE ARTICLE)
Headache Evaluation and Treatment by Primary Care Physicians in an
Emergency Department in the Era of Triptans
A retrospective review of emergency department visits for headache complaints
confirmed that migraine remains underdiagnosed and undertreated. Of 174 patients
diagnosed as having migraine, 26% received migraine-specific care. Of 90 patients
not diagnosed as having migraine, only 33% had adequate history documented
to exclude migraine as the diagnosis. Follow-up interviews of 86 patients
found that 18 (67%) of 27 patients not diagnosed as having migraine had migraine,
and 39 (66%) of 59 patients diagnosed as having migraine had associated medication
overuse (drug rebound).
(SEE ARTICLE)
A Randomized Multicenter Trial of Crotalinae Polyvalent Immune Fab
(Ovine) Antivenom for the Treatment for Crotaline Snakebite in the United
States
Rattlesnake envenomation is a limb- and life-threatening illness. The
current mainstay treatment of snakebite is antivenom; however, current products
are prone to cause serious allergic reactions. A new antivenom that is composed
of highly purified Fab fragments has been introduced. The results indicate
that it is safe and effective for the treatment of crotaline snakebite in
the United States, but likely needs to be administered differently than previous
antivenoms.
|
|
Schematic diagram of study.
|
(SEE ARTICLE)
CiteULike Connotea Del.icio.us Digg Reddit Technorati Twitter
What's this?
|